DE3750434D1 - Verwendung eines detektierbaren, markierten, Immunoglobulins oder eines Fragmentes davon zur Herstellung eines Mittels für den Nachweis eines Entzündungsherdes in vivo. - Google Patents

Verwendung eines detektierbaren, markierten, Immunoglobulins oder eines Fragmentes davon zur Herstellung eines Mittels für den Nachweis eines Entzündungsherdes in vivo.

Info

Publication number
DE3750434D1
DE3750434D1 DE3750434T DE3750434T DE3750434D1 DE 3750434 D1 DE3750434 D1 DE 3750434D1 DE 3750434 T DE3750434 T DE 3750434T DE 3750434 T DE3750434 T DE 3750434T DE 3750434 D1 DE3750434 D1 DE 3750434D1
Authority
DE
Germany
Prior art keywords
immunoglobulin
fragment
agent
preparation
detectable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3750434T
Other languages
English (en)
Other versions
DE3750434T2 (de
DE3750434T3 (de
Inventor
Robert H Rubin
William H Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE3750434D1 publication Critical patent/DE3750434D1/de
Publication of DE3750434T2 publication Critical patent/DE3750434T2/de
Publication of DE3750434T3 publication Critical patent/DE3750434T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Chemical Treatment Of Metals (AREA)
DE3750434T 1986-01-16 1987-01-16 Verwendung eines detektierbaren, markierten, Immunoglobulins oder eines Fragmentes davon zur Herstellung eines Mittels für den Nachweis eines Entzündungsherdes in vivo. Expired - Fee Related DE3750434T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81958586A 1986-01-16 1986-01-16
PCT/US1987/000079 WO1987004351A1 (en) 1986-01-16 1987-01-12 Method for the diagnosis and treatment of inflammation

Publications (3)

Publication Number Publication Date
DE3750434D1 true DE3750434D1 (de) 1994-10-06
DE3750434T2 DE3750434T2 (de) 1995-03-23
DE3750434T3 DE3750434T3 (de) 1999-04-08

Family

ID=25228549

Family Applications (3)

Application Number Title Priority Date Filing Date
DE0577225T Pending DE577225T1 (de) 1986-01-16 1987-01-16 Diagnose und Behandlung von Entzündung.
DE3750434T Expired - Fee Related DE3750434T3 (de) 1986-01-16 1987-01-16 Verwendung eines detektierbaren, markierten, Immunoglobulins oder eines Fragmentes davon zur Herstellung eines Mittels für den Nachweis eines Entzündungsherdes in vivo.
DE3752380T Expired - Fee Related DE3752380T2 (de) 1986-01-16 1987-01-16 Diagnose und Behandlung von Entzündung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE0577225T Pending DE577225T1 (de) 1986-01-16 1987-01-16 Diagnose und Behandlung von Entzündung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3752380T Expired - Fee Related DE3752380T2 (de) 1986-01-16 1987-01-16 Diagnose und Behandlung von Entzündung

Country Status (9)

Country Link
EP (2) EP0577225B9 (de)
JP (1) JP2515357B2 (de)
AT (2) ATE110572T1 (de)
AU (1) AU597032B2 (de)
CA (1) CA1288688C (de)
DE (3) DE577225T1 (de)
ES (2) ES2053403T3 (de)
GR (1) GR940300027T1 (de)
WO (1) WO1987004351A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004351A1 (en) * 1986-01-16 1987-07-30 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
CA2016235C (en) * 1989-05-09 2002-03-12 Alan J. Fischman Labeled chemotactic peptides to image focal sites of infection or inflammation
EP0485664A1 (de) * 1990-11-13 1992-05-20 Mallinckrodt Diagnostica (Holland) B.V. Verfahren zur Herstellung von einem diagnostischen Mittel zur Feststellung von Entzündungen
ATE175976T1 (de) * 1993-10-22 1999-02-15 Nihon Mediphysics Co Ltd Peptide mit affinität für entzündungen und deren radiomarkierte, diagnostische zusammensetzungen
DE19514088A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004464B (en) * 1977-06-30 1982-01-13 Cehovic G Method of testing inflammation
US4315906A (en) * 1979-05-21 1982-02-16 New England Nuclear Corporation Cold insoluble globulin, its purification and use
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
GB2101407A (en) * 1981-05-14 1983-01-12 Bulpitt And Sons Limited Automatic electric kettle
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
GR850552B (de) * 1984-03-07 1985-07-05 Du Pont
US4636380A (en) * 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
GB8426470D0 (en) * 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
AU597877B2 (en) * 1984-12-26 1990-06-14 Teijin Limited Anti-pseudomonas aeruginosa human monoclonal antibody
WO1987004351A1 (en) * 1986-01-16 1987-07-30 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
GB8610202D0 (en) * 1986-04-25 1986-05-29 Technology Licence Co Ltd Monoclonal antibodies
GB8621910D0 (en) * 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies

Also Published As

Publication number Publication date
ES2053403T1 (es) 1994-08-01
WO1987004351A1 (en) 1987-07-30
ATE283710T1 (de) 2004-12-15
EP0241106A2 (de) 1987-10-14
AU597032B2 (en) 1990-05-24
DE3750434T2 (de) 1995-03-23
ES2053403T3 (es) 2005-06-01
ES2056812T5 (es) 1998-11-16
DE3752380T2 (de) 2005-11-03
JPS63502280A (ja) 1988-09-01
EP0577225B1 (de) 2004-12-01
CA1288688C (en) 1991-09-10
JP2515357B2 (ja) 1996-07-10
DE3750434T3 (de) 1999-04-08
EP0241106B1 (de) 1994-08-31
EP0241106B2 (de) 1998-07-08
GR940300027T1 (en) 1994-05-31
ES2056812T3 (es) 1994-10-16
EP0577225A1 (de) 1994-01-05
DE577225T1 (de) 1994-09-22
AU6937787A (en) 1987-08-14
EP0577225B9 (de) 2005-03-02
EP0241106A3 (en) 1989-02-08
DE3752380D1 (de) 2005-01-05
ATE110572T1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
DE3382767D1 (de) Ein Verfahren zur Herstellung eines Antikörpers, der zur Bestimmung der Anwesenheit eines menschlichen Oncogens befähigt ist.
ES513992A0 (es) "un metodo para detectar sangre humana oculta en muestras de deposicion humana".
DE69633973D1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
ATE145285T1 (de) Nachweis einer neurologischen krankheit oder einer funktionsstörung
ES2132272T3 (es) Procedimiento para la determinacion de aductos de hemoglobina.
NO954897L (no) Fremgangsmåte for å bestemme et individs inflammasjonsindeks fra hele blodfibrinogen og hematokrit eller hemoglobinmålinger
DE3750434D1 (de) Verwendung eines detektierbaren, markierten, Immunoglobulins oder eines Fragmentes davon zur Herstellung eines Mittels für den Nachweis eines Entzündungsherdes in vivo.
ATE329265T1 (de) Verfahren zur instrumentellen bestimmung einer sich zeitabhängig ändernden messgrösse
DE3587542D1 (de) Verfahren zur Diagnose in vitro von menschlichen Cytomegalovirusinfektionen und Anwendung von monoklonalen Antikörpern gegen Cytomegaloviren, die mit einer cytomegalovirusinduzierten Proteinkinase reagieren.
ATE349703T1 (de) Kombination von crp und d-dimer zur diagnose von tiefer venenthrombose
DE3650635D1 (de) Monoklonale Antikörper
DE69424974T2 (de) Überwachung von Patienten mit Dickdarmkrebs durch Messung von NCA 50/90 im Blut
EP0621480A3 (de) Diagnose und Überwachung von Patienten mit Lungenkrebs durch Messung von NCA 50/90 im Blut.
SE9401457L (sv) Mätning av blodgaser
DE122478T1 (de) Verfahren zur herstellung eines monoklonalen antikoerpers mit spezifizitaet fuer vernetzte fibrinderivate und ein testverfahren mittels dieses antikoerpers.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8339 Ceased/non-payment of the annual fee